Circulation, Vol 84, 15-22, Copyright © 1991 by American Heart Association
P Theroux, M Baird, M Juneau, W Warnica, P Klinke, W Kostuk, P Pflugfelder, E Lavallee, C Chin and E Dempsey
BACKGROUND. Silent myocardial ischemia is an adverse prognostic marker in
patients with coronary disease; however, controlled data on the effect of
treatment are sparse and contradictory, and the relations among the
occurrence of ST segment depression, drug efficacy, and heart rate are
unclear. METHODS AND RESULTS. Sixty patients with stable coronary artery
disease, a positive treadmill exercise test and asymptomatic ST segment
depression on ambulatory electrocardiographic recording were assessed in a
multicenter, double-blind, placebo- controlled, cross-over trial. Treadmill
exercise tests and 72-hour electrocardiographic recordings were obtained at
the end of two 2-week treatment periods with sustained-release diltiazem
180 mg b.i.d. or equivalent placebo. Episodes of asymptomatic ST depression
decreased by 50% or more in 70% of the patients from a median number of 4.5
(range, 0-19) to 1.5 (range, 0-13) (p = 0.0001); their cumulative duration
also decreased from 78.5 (range, 0-60) to 24.5 (range, 0-411) minutes (p =
0.001). No circadian variation was found in the efficacy of diltiazem. The
occurrence of ischemic type ST segment depression was modulated by changes
in heart rate rather than by absolute heart rate. Diltiazem also improved
exercise test end points but to a lesser extent. Time to ST segment
depression increased to 341 +/- 148 from 296 +/- 154 seconds (p = 0.005).
Although less frequent with diltiazem administration (45 versus 54
patients, p less than 0.03), exercise-induced ST depression was more often
asymptomatic (98% versus 72% of patients, p less than 0.0001). CONCLUSIONS.
Diltiazem reduces the frequency and severity of ischemic type ST depression
in patients with stable coronary artery disease.
ARTICLES
Effect of diltiazem on symptomatic and asymptomatic episodes of ST segment depression occurring during daily life and during exercise
Canadian Multicenter Diltiazem Study Group, Montreal.
This article has been cited by other articles:
![]() |
G. Cice, A. Di Benedetto, A. D'Andrea, S. D'Isa, L. Ferrara, P. E. Russo, A. Iacono, and R. Calabro Sustained-Release Diltiazem Reduces Myocardial Ischemic Episodes in End-Stage Renal Disease: A Double-Blind, Randomized, Crossover, Placebo-Controlled Trial J. Am. Soc. Nephrol., April 1, 2003; 14(4): 1006 - 1011. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Tzivoni, H. Kadr, S. Braat, W. Rutsch, J. A. Ramires, and I. Kobrin Efficacy of Mibefradil Compared With Amlodipine in Suppressing Exercise-Induced and Daily Silent Ischemia : Results of a Multicenter, Placebo-Controlled Trial Circulation, October 21, 1997; 96(8): 2557 - 2564. [Abstract] [Full Text] |
||||
![]() |
North of England Stable Angina Guideline Developme North of England evidence based guidelines development project: summary version of evidence based guideline for the primary care management of stable angina BMJ, March 30, 1996; 312(7034): 827 - 832. [Full Text] |
||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1991 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |